Unlock instant, AI-driven research and patent intelligence for your innovation.

GAS57 mutant antigens and GAS57 antibodies

a technology of mutant antigens and antibodies, applied in the field of immunology and vaccinology, can solve problems such as hammering its use in a vaccine composition

Active Publication Date: 2012-10-16
GLAXOSMITHKLINE BIOLOGICALS SA
View PDF137 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The GAS57 mutants and antibodies effectively prevent S. pyogenes infections by reducing IL-8 cleavage while maintaining protective immunity, addressing the side effect concerns of wild-type GAS57 antigens.

Problems solved by technology

2006). This property of GAS57 may hamper its use in a vaccine composition, due to possible side e

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • GAS57 mutant antigens and GAS57 antibodies
  • GAS57 mutant antigens and GAS57 antibodies
  • GAS57 mutant antigens and GAS57 antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

Purified Wild-Type Recombinant GAS57 Cleaves IL-8 and Other CXC Cytokines

[0329]Wild-type GAS57 was expressed and purified from E. coli either as His-tagged or untagged protein. All variants were expressed without the N-terminal leader sequence and without the C-terminal transmembrane domain (see SEQ ID NOS:78 and 79). In detail, the gas57 gene was PCR amplified from M1_SF370 genome using the following primers:

[0330]

(SEQ ID NO: 69)57F,GTGCGT GCAGATGAGCTAAGCA(SEQ ID NO: 70)57R,GCGT GGCTTTTGCTGTTGCTGAGGT(SEQ ID NO: 71)57stopR,GCGT TTAGGCTTTTGCTGTTGCTGAGGT.

[0331]Primers 57F and 57R were used to obtain the His-tagged form, while primers 57F and 57stopR were used to obtain the untagged form. The PCR products were digested with NdeI-XhoI and ligated respectively with pET21b+ and pet24b+ cut with the same enzymes.

[0332]E. coli BL21(DE3) electrocompetent cells were transformed with the ligation reactions. Kanamycin resistant colonies carrying the plasmid with the correct insert (pET21—57his ...

example 2

Preparation of GAS57 Mutants

[0336]By comparison with C5a protease (FIG. 2), three amino acids in the GAS57 were identified that putatively constitute the catalytic site of the protease: D151, H279 and S617. In order to obtain an inactive form of the enzyme, nucleotide substitutions resulting in amino acid changes D151A and / or S617A were introduced in the GAS57 coding sequence by Splicing by Overlapping Extension PCR (SOE-PCR).

[0337]Substitution D151A

[0338]Three PCR reactions were carried out:

[0339]

PCR reactionTemplatePrimersPCR1 genomic57F, GTGCGT GCAGATGAG(360SF370CTAAGCA; SEQ ID NO: 69bps)57mutDR1, CCCTGTGGCAATAACTGCGAC; SEQ ID NO: 72PCR2genomic57mutDF1, cgCAGTTATTGcCACAGGGAT,(910SF370SEQ ID NO: 73bp)57mutSalR, CTGACTGA AGACTCTGAATAGATG, SEQ ID NO: 74PCR3PCR1,57F(1270PCR257mutSalRbps)

[0340]PCR product 3 was then digested with Nde-Sal and introduced in pET21—57his digested with the same enzymes. Clones containing the correct in-frame substitutions (pET21—57his_D151A) were selected ...

example 3

Point Mutation D151A Results in Inactivation of GAS57 Proteolytic Activity

[0348]GAS57 mutant D151A was expressed as a recombinant His-tagged protein. Two types of assays demonstrated that this mutant has lost the ability to cleave IL-8.

[0349]SDS-PAGE

[0350]IL-8 was incubated with wild-type GAS57 or the GAS57 mutant D151A. The incubation mixtures were loaded on SDS-PAGE and revealed by silver staining. The results are shown in FIG. 3. Wild-type GAS57 (lanes 2 and 3) released two bands: 8 kDa (active form) and 6 kDa (inactive cleaved IL-8). In contrast, the GAS57 D151A mutant released only one band, which corresponded to uncleaved IL-8, as in the control reaction (without enzyme).

[0351]ELISA

[0352]IL-8 was incubated with wild-type GAS57 or the GAS57 mutant D151A at three different concentrations, and the incubation mixtures were tested for the presence of uncleaved IL-8 using an antibody which is specific for the cytokine but which is unable to recognize the cleaved inactive form. The r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides mutants of GAS57 which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The mutants are useful, inter alia, in vaccine compositions to induce protection against S. pyogenes. The antibodies are useful, e.g., as therapeutics for treating S. pyogenes infections.

Description

[0001]This application is a national phase application of PCT / IB2008 / 003078 filed on Sep. 12, 2008 and published in English as WO 2009 / 034473 on Mar. 19, 2009. PCT / IB2008 / 003078 claims the benefit of Ser. No. 60 / 971,637 filed on Sep. 12, 2007.[0002]This application incorporates by reference the contents of a 756 kb text file created on Mar. 3, 2010 and named “PAT052285_sequencelisting.txt,” which is the sequence listing for this application.FIELD OF THE INVENTION[0003]This invention is in the fields of immunology and vaccinology. In particular, it relates to antigens derived from Streptococcus pyogenes and their use in immunization.BACKGROUND OF THE INVENTION[0004]S. pyogenes (Group A Streptococcus; GAS) antigen GAS57, expressed as recombinant protein and purified from E. coli, induces protective activity against a lethal challenge with S. pyogenes in mice. However, GAS57 is a protease which cleaves and inactivates human chemokines such as interleukin-8 (IL-8) (Edwards et al., J. In...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K39/09A61K39/02C07K1/00A61K38/00A61K39/00
CPCA61K39/092C07K14/315C07K16/40C07K16/1275A61K2039/522Y10S530/825A61K38/164A61K38/18A61K38/19A61K38/22A61P31/04Y02A50/30A61K45/06A61K2039/6037A61K2039/6043A61K2039/6068C07K14/22C07K14/235C07K14/285C07K14/33C07K14/475C07K14/52C07K14/575C07K2319/00C07K2319/55
Inventor MARGARIT Y ROS, IMMACULADAGRANDI, GUIDOZINGARETTI, CHIARA
Owner GLAXOSMITHKLINE BIOLOGICALS SA